He stated that the episode of the last six months showed just how brutally efficient the price discovery process is, in any ...

Novavax Inc. closed 61.59% short of its 52-week high of $17.81, which the company achieved on July 26th.

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.

Pfizer's COVID vaccine (Comirnaty) is fully approved for patients ages 12 and up, and authorized for kids ages 6 months ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., who has pushed for changes around mRNA ...

Unlike Drs. Adam Cifu and John Mandrola, I do not constantly boast of my "nuance" or claim to be a master of "clinical ...

Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated ...

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

Moderna stock surged on Tuesday amid what has been a lively past few days for the pharmaceutical industry. The tumultuous ...

Major health groups sue HHS and Robert F. Kennedy Jr. over COVID-19 vaccine policy changes for children and pregnant ...